Site icon

5 Best and Worst Performing Mid-Cap Stocks in Q4 2022 – Darlinez News.

<p> &lbrack;ad&lowbar;1&rsqb;<br &sol;>&NewLine;<&sol;p>&NewLine;<div>&NewLine;<div class&equals;"entry-content column content primary is-two-thirds">&NewLine;<div class&equals;"" style&equals;"padding-bottom&colon; 10px&semi;">&NewLine;<div class&equals;"">&NewLine;<p>&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<span class&equals;"tag is-dark is-uppercase">Investing<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;p>&NewLine;<div class&equals;"byline-container">&NewLine;<div class&equals;"post-date is-italic has-text-grey is-size-7 has-text-weight-medium ">&NewLine;<p>January 19&comma; 2023 10&colon;53 pm<&sol;p>&NewLine;<&sol;p><&sol;div>&NewLine;<&sol;p><&sol;div>&NewLine;<&sol;p><&sol;div>&NewLine;<&sol;p><&sol;div>&NewLine;<&sol;p><&sol;div>&NewLine;<p>Mid-cap stocks are proving to be an attractive investment option over the past few years&period; In fact&comma; the S&&num;038&semi;P MidCap 400 index has performed better than the S&&num;038&semi;P 500 and the S&&num;038&semi;P SmallCap 600 index for most of the past 20 years &lpar;through 2015&rpar;&comma; according to a report by S&&num;038&semi;P Global&period; Going forward&comma; most analysts are expecting a good show from quality mid-cap stocks in 2023&period; Let’s take a look at the five best and worst performing mid-cap stocks in Q4 2022&period;<&sol;p>&NewLine;<h2>Five Best Performing Mid-Cap Stocks In Q4 2022<&sol;h2>&NewLine;<p>We have taken the fourth quarter 2022 return numbers of mid-cap stocks from finviz&period;com to rank the five best and worst performing mid-cap stocks in Q4 2022&period; Here are the five best performing mid-cap stocks in Q4 2022&colon;<&sol;p>&NewLine;<h3>5&period; Prometheus Biosciences &lpar;86&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2016 and headquartered in San Diego&comma; Calif&period;&comma; this company focuses on developing therapeutics and companion diagnostics for gastroenterology and autoimmune diseases&period; Prometheus Biosciences Inc &lpar;NASDAQ&colon;RXDX&rpar; shares are up by almost 9&percnt; year to date and up almost 251&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Prometheus Biosciences shares are trading above &dollar;122 with a 52-week range of &dollar;21&period;50 to &dollar;122&period;75&comma; giving the company a market capitalization of more than &dollar;5&period;5 billion&period;<&sol;p>&NewLine;<h3>4&period; Vaxcyte &lpar;100&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2013 and headquartered in San Carlos&comma; Calif&period;&comma; this company develops vaccines for infectious diseases&period; Vaxcyte Inc &lpar;NASDAQ&colon;PCVX&rpar; shares are down by over 7&percnt; year to date but are up by over 152&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Vaxcyte shares are trading above &dollar;44 with a 52-week range of &dollar;16&period;78 to &dollar;49&period;31&comma; giving the company a market cap of more than &dollar;3&period;5 billion&period;<&sol;p>&NewLine;<h3>3&period; Maxar Technologies &lpar;176&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 1969 and headquartered in Westminster&comma; Colo&period;&comma; this company provides space technology solutions&period; Maxar Technologies Inc &lpar;NYSE&colon;MAXR&rpar; shares are down by almost 1&percnt; year to date and up by over 89&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Maxar Technologies shares are trading above &dollar;51 with a 52-week range of &dollar;17&period;51 to &dollar;51&period;93&comma; giving the company a market cap of more than &dollar;3&period;8 billion&period;<&sol;p>&NewLine;<h3>2&period; Immunovant &lpar;218&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2018 and headquartered in New York City&comma; this company focuses on treatments to enable normal lives for patients with autoimmune diseases&period; Immunovant Inc &lpar;NASDAQ&colon;IMVT&rpar; shares are down by almost 2&percnt; year to date but are up by over 150&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Immunovant shares are trading above &dollar;16&period;90 with a 52-week range of &dollar;3&period;15 to &dollar;20&period;24&comma; giving the company a market cap of more than &dollar;2&period;3 billion&period;<&sol;p>&NewLine;<h3>1&period; Madrigal Pharmaceuticals &lpar;347&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2011 and headquartered in Fort Washington&comma; Pa&period;&comma; this company develops therapeutic candidates for treating cardiovascular&comma; metabolic&comma; and liver diseases&period; Madrigal Pharmaceuticals Inc &lpar;NASDAQ&colon;MDGL&rpar; shares are up by almost 4&percnt; year to date and up over 340&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Madrigal Pharmaceuticals shares are trading above &dollar;300 with a 52-week range of &dollar;52&period;33 to &dollar;315&period;45&comma; giving the company a market capitalization of more than &dollar;5 billion&period;<&sol;p>&NewLine;<h2>Five Worst Performing Mid-Cap Stocks In Q4 2022<&sol;h2>&NewLine;<p>Here are the five worst performing mid-cap stocks in Q4 2022&colon;<&sol;p>&NewLine;<h3>5&period; Applovin &lpar;-46&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2011 and headquartered in Palo Alto&comma; Calif&period;&comma; this company operates as a mobile marketing platform&period; Applovin Corp &lpar;NASDAQ&colon;APP&rpar; shares are up by almost 2&percnt; year to date but are down by almost 85&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Applovin shares are trading above &dollar;10&period;40 with a 52-week range of &dollar;9&period;14 to &dollar;76&period;38&comma; giving the company a market capitalization of more than &dollar;4 billion&period;<&sol;p>&NewLine;<h3>4&period; Affirm Holdings &lpar;-48&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2012 and headquartered in San Francisco&comma; this company provides a platform for digital and mobile-first commerce&period; Affirm Holdings Inc &lpar;NASDAQ&colon;AFRM&rpar; shares are up by over 34&percnt; year to date but are down by over 79&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Affirm Holdings shares are trading above &dollar;12&period;90 with a 52-week range of &dollar;8&period;62 to &dollar;83&period;57&comma; giving the company a market cap of more than &dollar;3&period;8 billion&period;<&sol;p>&NewLine;<h3>3&period; Guardian Health &lpar;-50&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2021 and headquartered in Palo Alto&comma; Calif&period;&comma; it is a precision oncology company that deals in the treatment of cancer&period; Guardant Health Inc &lpar;NASDAQ&colon;GH&rpar; shares are up by almost 18&percnt; year to date but are down by over 56&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Guardant Health shares are trading &dollar;32 with a 52-week range of &dollar;24&period;63 to &dollar;78&period;34&comma; giving the company a market cap of more than &dollar;3&period;1 billion&period;<&sol;p>&NewLine;<h3>2&period; Rogers &lpar;-51&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 1832 and headquartered in Chandler&comma; Ariz&period;&comma; this company makes and sells engineered materials and components for mission critical applications&period; Rogers Corp &lpar;NYSE&colon;ROG&rpar; shares are up by almost 10&percnt; year to date but are down by over 52&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Rogers shares are trading above &dollar;130 with a 52-week range of &dollar;98&period;45 to &dollar;274&period;51&comma; giving the company a market cap of more than &dollar;2&period;4 billion&period;<&sol;p>&NewLine;<h3>1&period; Rumble &lpar;-51&percnt;&rpar;<&sol;h3>&NewLine;<p>Founded in 2013 and headquartered in New York City&comma; it is an online neutral video platform&period; Rumble Inc &lpar;NASDAQ&colon;RUM&rpar; shares are up by almost 68&percnt; year to date but are down by almost 21&percnt; in the last year&period;<&sol;p>&NewLine;<p>As of this writing&comma; Rumble shares are trading above &dollar;9&period;55 with a 52-week range of &dollar;5&period;81 to &dollar;18&period;52&comma; giving the company a market capitalization of more than &dollar;3&period;7 billion&period;<&sol;p>&NewLine;<p><i>This article originally appeared on ValueWalk<&sol;i><&sol;p>&NewLine;<p>&Tab;&Tab;&Tab;&Tab;<&excl;-- &num;post-footer--><&sol;p><&sol;div>&NewLine;

Exit mobile version